Central Banks Shift to "Higher for Longer" Rates Amid Inflation: As a biotech company, Coherus Oncology often relies on external funding for R&D and may not yet be consistently profitable. Higher interest rates increase the cost of borrowing and make it more expensive to raise capital, potentially impacting its growth initiatives and financial stability.

Iran War Escalation Drives US Inflation: Increased inflation could lead to higher operational costs for Coherus Oncology, including expenses for research and development, manufacturing, and supply chain logistics. This could compress margins and make achieving profitability more challenging.

Strait of Hormuz Closure Sustains Oil Price Volatility: Elevated and volatile oil prices resulting from geopolitical tensions can lead to higher transportation costs for raw materials, laboratory supplies, and distribution of finished products. This impacts the company's supply chain efficiency and overall operational expenses.